Trea and Discovery Ventures Launch Trea Healthcare Ventures

A new fund to invest in diseases that have no cure was created. The Spanish investment fund manager Trea Am, together with the international firm specializing in health investment funds, Discovery Ventures, have created Trea Healthcare Ventures, a new health fund for €25 million.

Trea Healthcare Ventures aims to invest in therapeutic advances that prevent, cure, or treat diseases that have no cure today. For this, it is intended to use forms of medicine that are still in the process of growth, such as cell therapies, genetics, nano-biotechnology, artificial intelligence, bionics, or tissue engineering.

The fund is part of article nine of the European Sfdr regulations that focus on improving the quality of life and health of the population as a whole, through the use of therapeutic tools focused on biotechnology, that is, on tools that they are still in the development process.

The companies in which Trea Healthcare Ventures will invest are those that have “therapeutic treatments that have significant clinical benefit and that target large populations of patients with a high degree of unmet medical need, with next-generation solutions,” according to the brochure sent by the firm to the National Securities Market Commission (Cnmv).

If you want to find more details about Trea Healthcare Ventures and find the most important business news of the day, download for free our companion app. Available for free, for both Android and iOS devices, the Born2Invest mobile app brings you the most important market updates.

Trea Healthcare Ventures will invest in about twenty companies

Trea Healthcare Ventures will focus on around twenty-25 companies and will have an investment portfolio that can be common, preferred, Safe (Simple Agreements for Future Equity) shares, as well as convertible bonds. Likewise, the companies to which it will be addressed will be located in Europe and the United States.

Company regulations prevent investing more than 35% in companies that belong to the same business group and more than 25% in investable assets at the time of investing in the same company.

Trea Am allied with The Fund at the end of 2022 to create a fund focused on start-ups

The launch of the new Trea Am fund together with Discovery Ventures follows the recent launch of the Spanish firm on the US market. At the end of 2022, Trea Am allied with the American manager The Fund in the creation of The Fund Trea US Ventures, with a value of €20 million, which serves as a vehicle for both companies to invest in start-ups in their initial phase in the American country.  

Discovery Ventures is a manager that specializes in the healthcare field and has offices in Paris, London, and New York. The firm has made investments in companies such as Quethera, Orchard Therapeutics, and Gensight.

__

(Featured image by TBIT via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.